Investigators conducted a retrospective study to better understand whether there is an equally shared risk for C difficile infection across immunosuppressant classes.
A multidisciplinary panel comprising members from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America created guidelines for health care professionals caring for patients with C difficile infection.
Investigators evaluated the safety and effectiveness of bezlotoxumab to prevent recurrent C difficile infection in patients having undergone solid organ or hematopoietic cell transplantation.
Investigators assessed the immune response to Clostridioides difficile in immunocompromised patients.
Investigators assessed whether choice of antibiotic has an impact on shedding of Clostridioides difficile spores in hospitalized patients.
A team of investigators evaluated outcomes following probiotic use for primary prevention of Clostridioides difficile infection in hospitalized patients.
Authors recommend against probiotics for prevention of CDI; in those with CDI recurrence, FMT recommended to prevent further recurrence.
To develop microbiome drugs, scientists will need to address challenges in safety, uniformity, and delivery.
Study authors tested the effect of disinfectant wipes on spore loads and cross-contamination risk for Clostridioides difficile.
Publication of the revised clinical practice guidelines for Clostridioides difficile infection was followed by significant increases in use of oral vancomycin and fidaxomicin, and a significant decrease in use of oral metronidazole.
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
As a result of a decline in healthcare–associated infections, the estimated burden of Clostridioides difficile infection in the United States decreased by an adjusted 24% from 2011 through 2017.
From 2011 to 2017, there was a decrease in the estimated national burden of Clostridium difficile infection.
Features of fecal microbiota at baseline and after antibiotic therapy may be predictive of recurrent Clostridiodes difficile infection in patients with and without ulcerative colitis.
A glutamate dehydrogenase test for Clostridioides difficile may reduce unnecessary isolation time for patients.
The FDA has approved fidaxomicin for the treatment of Clostridioides difficile-associated diarrhea in adult and pediatric patients aged 6 months and older.
Clostridioides difficile infection is associated with a large burden on the healthcare system in the United States.
Dual therapy with intravenous metronidazole and oral vancomycin is not superior to oral vancomycin alone in the treatment of Clostridioides difficile infections.
Asymptomatic carriers of C. difficile at significant risk for progression to symptomatic infection
Toxin enzyme immunoassay more accurately identifies severe C difficile infections from strains more likely to cause recurrence, but otherwise had similar results for complications and mortality compared with the standard nucleic acid amplification test.